-
Article
Open AccessPlasma ALS and Gal-3BP differentiate early from advanced liver fibrosis in MASLD patients
Metabolic dysfunction-associated steatotic liver disease (MASLD) is estimated to affect 30% of the world’s population, and its prevalence is increasing in line with obesity. Liver fibrosis is closely related t...
-
Article
Ezurpimtrostat, A Palmitoyl-Protein Thioesterase-1 Inhibitor, Combined with PD-1 Inhibition Provides CD8+ Lymphocyte Repopulation in Hepatocellular Carcinoma
Palmitoyl-protein thioesterase-1 (PPT1) is a clinical stage druggable target for inhibiting autophagy in cancer.
-
Article
Defining textbook outcome for selective internal radiation therapy of hepatocellular carcinoma: an international expert study
A textbook outcome (TO) is a composite indicator covering the entire intervention process in order to reflect the “ideal” intervention and be a surrogate for patient important outcomes. Selective internal radi...
-
Article
Evolution of Thoracic Duct Congestion after Portal Decompression by TIPS in Cirrhotic Patients
To evaluate the thoracic duct (TD) diameter on CT scan in a population of cirrhotic patients before and after relief of portal hypertension by transjugular intrahepatic portosystemic shunt (TIPS) insertion. To...
-
Article
Open AccessClinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis
In HCV-infected patients with advanced liver disease, the direct antiviral agents-associated clinical benefits remain debated. We compared the clinical outcome of patients with a previous history of decompensa...
-
Article
Open AccessCorrection: Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression
-
Article
Open AccessPhase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression
This Phase 1b/2 study evaluated tepotinib, a highly selective MET inhibitor, in US/European patients with sorafenib pretreated advanced hepatocellular carcinoma (aHCC) with MET overexpression.
-
Article
Open AccessNASH limits anti-tumour surveillance in immunotherapy-treated HCC
Hepatocellular carcinoma (HCC) can have viral or non-viral causes1–5. Non-alcoholic steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved for treating HCC, but biomarker-based stra...
-
Article
Correction to: Differentiating focal nodular hyperplasia from hepatocellular adenoma: Is hepatobiliary phase MRI (HBP-MRI) using linear gadolinium chelates always useful?
The original version of this article unfortunately contained a mistake. There was an error in the last sentence of the summary and the last sentence of the discussion. It should read as “On HBP, all FNH appear...
-
Article
Differentiating focal nodular hyperplasia from hepatocellular adenoma: Is hepatobiliary phase MRI (HBP-MRI) using linear gadolinium chelates always useful?
To assess the value of Hepatobiliary phase MRI (HPB-MRI) to differentiate FNH and HCA, and evaluate its impact on diagnostic accuracy, diagnostic confidence, inter-observer variability, and patient clinical ma...
-
Article
Open AccessFunctional imaging of hepatocellular carcinoma using diffusion-weighted MRI and 18F-FDG PET/CT in patients on waiting-list for liver transplantation
To compare the apparent diffusion coefficient (ADC) on diffusion-weighted imaging (DWI) with the standardized uptake values (SUV) measured by18F-FDG-PET/CT in naïve hepatocellular carcinoma (HCC) nodules, and to ...
-
Article
ALDH3A1 is overexpressed in a subset of hepatocellular carcinoma characterised by activation of the Wnt/ß-catenin pathway
Aldehyde dehydrogenase isoforms, ALDH1A1 and ALDH3A1, are associated with poor clinical outcome and resistance to chemotherapy in a wide variety of human malignancies. So far, their expression and prognostic s...
-
Chapter
mTOR and Cancer Therapy: Clinical Development and Novel Prospects
mTOR, a pivotal signal transduction protein involved in multiple cellular functions in tumors at the level of cancer and stroma cells, represents an attractive target for cancer therapy. Rapamycin and several ...
